Filtered By:
Condition: Thrombosis
Drug: Clopidogrel
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 536 results found since Jan 2013.
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation
The objective of this study was to validate the ability of ABCD-GENE score to predict risk for atherothrombotic events in a diverse, real-world population of clopidogrel-treated PCI patients who received clinical CYP2C19 genotyping to guide antiplatelet therapy. A total of 2341 adult patients who underwent PCI, were genotyped for CYP2C19, and received treatment with clopidogrel across four institutions were included (mean age 64±12 years, 35% female, 20% Black). The primary outcome was major atherothrombotic events, defined as the composite of all-cause death, myocardial infarction, ischemic stroke, stent thrombosis, or r...
Source: Clinical Pharmacology and Therapeutics - April 16, 2022 Category: Drugs & Pharmacology Authors: Cameron D Thomas Francesco Franchi Ellen C Keeley Joseph S Rossi Marshall Winget R David Anderson Alyssa L Dempsey Yan Gong Megan N Gower Richard A Kerensky Natasha Kulick Jean G Malave Caitrin W McDonough Ian R Mulrenin Petr Starostik Amber L Beitelshees Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy
CONCLUSIONS: In this retrospective study, aggressive periprocedural antiplatelet strategy led to improved stent patency and clinical outcomes, without increased HT. Further prospective randomized research is warranted to identify the optimal combination of antiplatelet agents for emergent carotid stenting in the setting of acute stroke.PMID:35253529 | DOI:10.1177/15910199221083112
Source: Interventional Neuroradiology - March 7, 2022 Category: Radiology Authors: Raoul Pop Fran çois Severac Anca Hasiu Dan Mihoc Pierre H Mangin Salvatore Chibbaro Mihaela Simu Raluca Tudor Roxana Gheoca V éronique Quenardelle Val érie Wolff R émy Beaujeux Source Type: research
P2Y12 Reaction Units and Clinical Outcomes in Acute Large Artery Atherosclerotic Stroke: A Multicenter Prospective Study
CONCLUSIONS: Acute PRU evaluation possesses predictive value for recurrent ischemic stroke, especially within 7 days in AIS/TIA with LAA.PMID:35249906 | DOI:10.5551/jat.63369
Source: Journal of Atherosclerosis and Thrombosis - March 7, 2022 Category: Cardiology Authors: Kazuki Fukuma Hiroshi Yamagami Masafumi Ihara Tomotaka Tanaka Toshiyuki Miyata Shigeki Miyata Koichi Kokame Kunihiro Nishimura Yuriko Nakaoku Haruko Yamamoto Mikito Hayakawa Kenji Kamiyama Yukiko Enomoto Ryo Itabashi Eisuke Furui Yasuhiro Manabe Masayuki Source Type: research
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy
CONCLUSIONS: In this retrospective study, aggressive periprocedural antiplatelet strategy led to improved stent patency and clinical outcomes, without increased HT. Further prospective randomized research is warranted to identify the optimal combination of antiplatelet agents for emergent carotid stenting in the setting of acute stroke.PMID:35253529 | DOI:10.1177/15910199221083112
Source: Interventional Neuroradiology - March 7, 2022 Category: Radiology Authors: Raoul Pop Fran çois Severac Anca Hasiu Dan Mihoc Pierre H Mangin Salvatore Chibbaro Mihaela Simu Raluca Tudor Roxana Gheoca V éronique Quenardelle Val érie Wolff R émy Beaujeux Source Type: research
P2Y12 Reaction Units and Clinical Outcomes in Acute Large Artery Atherosclerotic Stroke: A Multicenter Prospective Study
CONCLUSIONS: Acute PRU evaluation possesses predictive value for recurrent ischemic stroke, especially within 7 days in AIS/TIA with LAA.PMID:35249906 | DOI:10.5551/jat.63369
Source: Journal of Atherosclerosis and Thrombosis - March 7, 2022 Category: Cardiology Authors: Kazuki Fukuma Hiroshi Yamagami Masafumi Ihara Tomotaka Tanaka Toshiyuki Miyata Shigeki Miyata Koichi Kokame Kunihiro Nishimura Yuriko Nakaoku Haruko Yamamoto Mikito Hayakawa Kenji Kamiyama Yukiko Enomoto Ryo Itabashi Eisuke Furui Yasuhiro Manabe Masayuki Source Type: research
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy
CONCLUSIONS: In this retrospective study, aggressive periprocedural antiplatelet strategy led to improved stent patency and clinical outcomes, without increased HT. Further prospective randomized research is warranted to identify the optimal combination of antiplatelet agents for emergent carotid stenting in the setting of acute stroke.PMID:35253529 | DOI:10.1177/15910199221083112
Source: Interventional Neuroradiology - March 7, 2022 Category: Radiology Authors: Raoul Pop Fran çois Severac Anca Hasiu Dan Mihoc Pierre H Mangin Salvatore Chibbaro Mihaela Simu Raluca Tudor Roxana Gheoca V éronique Quenardelle Val érie Wolff R émy Beaujeux Source Type: research
Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
CONCLUSION: The preferred therapy after PCI in patients with AF is DAT with a NOAC and clopidogrel. In-hospital ischemic and bleeding events were rare. The recommended durations for combination therapy vary considerably.PMID:35243515 | DOI:10.1007/s00059-022-05099-6
Source: Herz - March 4, 2022 Category: Cardiology Authors: Uwe Zeymer Ralph Toelg Harm Wienbergen Hans-Peter Hobbach Alessandro Cuneo Raffi Bekeredjian Oliver Ritter Birgit Hailer Klaus Hertting Marcus Hennersdorf Werner Scholtz Peter Lanzer Harald Mudra Markus Schwefer Peter-Lothar Schwimmbeck Christoph Liebetra Source Type: research
